ILA

ISLAND PHA FPO [ILA]
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Healthcare · ASX Small Cap
$0.4800 +0.0%

Updated 14 Jul 2026 · Signals refresh every scan

Get alerts when ILA triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track ILA — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Trading above both moving averages — the trend is your friend here
  • Volume surging at 5.4x normal while price falls — heavy selling pressure
  • Beating the Small Ords index — relative strength of 1.39, so it's outpacing the pack
  • Trading above the 200-day average — the long-term trend is on your side
  • Adequate cash runway (7 quarters)
  • Very high P/S ratio (2330.6x)
  • Revenue in sharp decline (-58%)
  • EPS estimates revised downward (-10pts)
  • CANSLIM S: Tight float (46%)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (6.25%/day)
  • Altman Z-Score distress zone (1.77 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -58% — the top line is shrinking
Ask Scout AI about ILA
"What's driving ILA today?" "How does ILA compare to peers?" "Key risks for ILA?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Notification regarding unquoted securities - ILA
NONE Notification regarding unquoted securities - ILA
NONE Notification regarding unquoted securities - ILA
Announcement tone +3pts

Recent ASX Announcements

2026-07-13 Notification regarding unquoted securities - ILA
2026-07-13 Notification regarding unquoted securities - ILA
2026-07-13 Notification regarding unquoted securities - ILA
2026-07-13 Notification regarding unquoted securities - ILA
2026-07-12 Texas Biomed SOW accelerates pivotal FDA pathway PRICE SENSITIVE

Key Metrics

$146.5M
Market Cap
445K
Avg Volume
5.4x
Vol Ratio
$0.14 — $0.63
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-130.3%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 46%
LLeader vs LaggardpassRS: 16
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

109 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS -20.0%MEM -12.5%NTI +12.5%VBS +11.4%BDX +11.0%
Compare:ILA vs ECSILA vs MEMILA vs NTI
Scout Pro — Deeper Analysis for ILA
Try Pro free for 30 days
Share this analysis

Track ILA and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required